The Food and Drug Administration reported Wednesday that Johnson & Johnson’s single-dose vaccine to protect against COVID-19 was safe and 72% efficacious in the United States, setting it up for a quick authorization process in the coming days.

The FDA’s 62-page report showed that the single-shot vaccine developed by Johnson & Johnson-owned Janssen Pharmaceutical had an efficacy rate of 72% in its U.S.-based trial and 66% overall across three regions where the shot was tested. The vaccine is also 85% effective overall at preventing hospitalization and 100% effective at preventing death due to COVID-19.